India's pharmaceutical industry continues to hold global relevance, accounting for a significant share of the world's medication supply. As the nation exports pharmaceutical products to over 200 countries, industry experts like Chahat Aggarwal of StockGro project a strong growth trajectory for the sector in 2025. The Union Budget 2025, scheduled for release on 1st February, is expected to play a key role in boosting the pharmaceutical sector, which is valued at $50 billion in FY 2023-24.

Key Growth Drivers

The pandemic’s lasting impact exposed several challenges and opportunities within the industry. The pharmaceutical sector’s growth is driven by factors like increasing healthcare awareness, the expiry of patents, and government initiatives like the Production-Linked Incentive (PLI) scheme. These initiatives are expected to drive innovation, boost local production, and encourage foreign investments, leading to a healthier fiscal environment for the sector.

Research and Development (R&D)

While India is the third-largest pharmaceutical producer globally by volume, it lags in novel medication research. A significant push towards R&D investment in the Union Budget 2025 is anticipated to help India close the gap and possibly emerge as a world leader in pharmaceutical research. The government may increase incentives for innovation, promoting more clinical trials and drug development within the country.

Regulatory Framework and Simplification

India's complex regulatory environment has hindered smooth business operations within the pharmaceutical industry. Experts suggest that streamlining the approval processes and creating a unified regulatory authority for pharmaceuticals and medical devices would reduce bureaucratic delays. This would make the sector more attractive to global investors, further boosting India’s position as a leader in generic medicine production.

Medical Tourism Boost

Another significant contributor to the pharmaceutical sector’s growth is medical tourism. Experts predict that by 2026, India’s medical tourism industry will be worth $13 billion. With the Union Budget 2025, efforts to enhance healthcare infrastructure, simplify visa procedures, and offer tax incentives for foreign patients will position India as a preferred global healthcare destination. The growth of the pharmaceutical industry is crucial to this transformation.

Intellectual Property (IP) and Healthcare Focus

A major concern is the intellectual property approval process, where the average patent approval period in India currently spans 50 months, longer than the global standard. To attract international pharmaceutical companies, the government is looking to cut this time by approximately 30 months, aligning with global norms. The Union Budget 2025 is expected to prioritize improving intellectual property laws to create a more conducive environment for pharmaceutical investments.

Universal Healthcare and Preventive Care

The budget will also focus on universal healthcare and the promotion of preventive healthcare. Experts advocate for the increased allocation of funds for wellness initiatives and public health campaigns targeting issues like diabetes, anaemia, and lifestyle diseases. Additionally, the expansion of the Ayushman Bharat Pradhan Mantri Jan Aarogya Yojana (PMJAY) and targeted incentives for private healthcare providers are expected.

PLI Schemes and Domestic Production

India’s reliance on imports, particularly from China, for Active Pharmaceutical Ingredients (APIs) has sparked a call for more domestic production-linked incentives (PLI). Experts urge the Union Budget 2025 to focus on boosting local API production and reducing reliance on foreign suppliers. This, along with the PLI scheme, will enhance India's capability to supply high-quality medicines globally, while also securing a stronger domestic market.

Public Healthcare Spending

Healthcare spending in India is currently low compared to global standards. The budget 2025 is expected to address this by increasing the healthcare budget to 2.5%-3% of GDP, an important step towards building a sustainable healthcare infrastructure. The increase in spending will support growth in the pharmaceutical sector, providing better resources for both the public and private healthcare systems.

Sun Pharmaceuticals: A Stock to Watch

Sun Pharmaceuticals, a major player in the Indian pharmaceutical sector, is expected to benefit from the Union Budget 2025. With a solid revenue growth strategy and a focus on specialty drugs, Sun Pharma is poised to lead the way in this expanding market. Aggarwal recommends investors keep an eye on this stock as it continues to capitalize on the growth of the pharmaceutical industry.

Final Thoughts

As the global demand for affordable and high-quality medicines rises, India’s pharmaceutical industry is set to continue its leadership in the global market. The Union Budget 2025 will be pivotal in shaping the future of this essential sector. By addressing key areas like R&D, healthcare infrastructure, regulatory reforms, and domestic production incentives, the budget can propel India’s pharmaceutical industry to greater heights, positioning it to maintain its global leadership in the years to come.

For more Real-time Updates, Bookmark https://financesaathi.com

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.